Chemokine receptor binding polypeptides

US9328174B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Zarin Brown · Leatherhead, GB
• Michelle Bradley · Horsham, GB
• Steven John Charlton · Horsham, GB
• Gino Van Heeke · Gainesville, US
• Karen Cromie · Merelbeke, BE
• Bruno Dombrecht · Heusden, BE
• Soren Steffensen · Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, BE
• Judith Baumeister · Wuppertal, DE
• Marie-Paule Lucienne Armanda Bouche · Gentbrugge, BE
• Carlo Boutton · Wielsbeke, BE
• Marie-Ange Buyse · Merelbeke, BE
• Veerle Snoeck · Zingem, BE
• Stephanie Staelens · Wevelgem, BE

Key dates

• Filing date: May 3, 2013
• Grant date: May 3, 2016
• Expiry date: May 16, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to polypeptides directed against or specifically binding to CXC chemokine receptor 2 (“CXCR2”) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.